Cognito Therapeutics, a late clinical-stage neurotechnology company developing non-invasive therapies for neurodegenerative diseases, announced the close of an oversubscribed $105 million Series C financing round to support the advancement and commercialization of its Spectris platform for Alzheimer’s disease. The financing was led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital, with participation from new investors including New Vintage, Apollo Health Ventures, and Benvolio Group.
The company said the capital will support key milestones, including a pivotal clinical data readout, regulatory submission, and preparations for commercial launch anticipated in 2027.
Cognito’s lead product, Spectris, is an investigational at-home therapeutic platform designed to stimulate coordinated neural activity using non-invasive visual and auditory stimulation. The technology is intended to engage neural networks through natural sensory pathways with the goal of preserving cognition, daily function, and brain structure in patients diagnosed with Alzheimer’s disease.
According to the company, the series C funding will also support continued clinical development of the Spectris platform and expansion into additional neurodegenerative indications. These efforts will be pursued through Cognito’s network of brain health collaboratories, beginning with its collaboration with the WVU Rockefeller Neuroscience Institute.
The company’s HOPE pivotal study is fully enrolled, and Cognito expects to report top-line data later this year. Spectris remains an investigational device and has not yet been approved by the U.S. Food and Drug Administration.
Cognito Therapeutics is headquartered in Cambridge, Massachusetts and focuses on developing neuroprotective therapies to address central nervous system disorders. Early feasibility studies conducted by the company suggest the Spectris platform may help preserve cognitive function and slow brain atrophy in patients with mild to moderate Alzheimer’s disease.
KEY QUOTES:
“With this financing, we are entering a pivotal moment for our company, and for the patients and families waiting for new options in Alzheimer’s disease. Spectris has the potential to become the world’s first physician-prescribed, at-home neuroprotective therapy for patients diagnosed with Alzheimer’s, designed to preserve cognition and daily function. This funding allows us to make this therapy accessible to those who need it most.”
Christian Howell, Chief Executive Officer of Cognito Therapeutics
“Advancing precision medicine for Alzheimer’s disease by expanding the range of treatment options available to patients is critically important. Novel technologies like Cognito’s, which are non-invasive and accessible, will be an important part of the broad and comprehensive treatment approach that will define the future of Alzheimer’s care. Ultimately, we will be able to combine therapeutics, lifestyle interventions, and devices to treat each patient based on their individual risk profiles.”
Howard Fillit, MD, Co-Founder And Chief Science Officer Of The Alzheimer’s Drug Discovery Foundation
“Cognito represents a rare convergence of rigorous neuroscience research, clinical validation, elegant engineering, and a deep understanding of patient needs. Spectris has the potential to redefine how a broad category of neurodegenerative diseases are treated, by moving therapy into the home, reducing burden on patients and caregivers, and scaling impact globally. We are proud to continue supporting Cognito as it advances toward regulatory submission and broader clinical impact.”
Gerald Chan, ScD., Founder Of Morningside Ventures And Chairman Of The Board At Cognito Therapeutics
